Company Overview and News
2018-09-12 seekingalpha - 4
Discussion: Five Prime Therapeutics' (FPRX) FPA144 (bemarituzumab) plus chemotherapy completed Part 1 of a Phase 1/3 clinical trial evaluating treatment-naive patients with advanced gastric cancer (GC) or cancer of the gastroesophageal junction (GEJ). The trial now moves to its subsequent parts in Phase 3. Overall survival (OS) is the primary endpoint of the trial. Progression-free survival (PFS) and objective response rate (ORR) are the secondary endpoints.
CYCC MASI CYCCP ECYT JNJ ZLAB PRGO FPRX TCON
Perrigo Company plc (PRGO - Free Report) announced that the FDA has approved store brand over-the-counter (“OTC”) equivalent of Johnson & Johnson (JNJ - Free Report) owned Imodium Multi-Symptom Relief tablet. The drug is indicated for treating symptoms of diarrhea plus bloating, pressure and cramps.
JNJ LGNZZ LGND PRGO LGNYZ LGNXZ LGNDZ
2018-09-02 seekingalpha - 7
Greenlight's long/short ratio is at 96% long and 75% short compared to 111% long and 82% short last quarter.
TWX AZO MET BLMN DLTR TJX CEIX.WI SFM DSW CLPPZ AABA TWTR VNTR CLPR GLRE CNX.WI ADNT TWC XRX CNDT BHF ROKU GPS ATHN GRBK CCR MDCO NFLX PYPL HUN VOYA ESV ODP AAPL GM CEIX DDS XELA TPR TPX MU DG PRGO TSLA URBN FIVE CNX
2018-08-20 seekingalpha - 1
The following slide deck was published by Perrigo Company in conjunction with their 2018 Q2 earnings call.
Good morning, and welcome to the Perrigo Second Quarter 2018 Financial Results Conference Call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask question. Please note this event is being recorded.
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION<
(Reuters) - Perrigo Co Plc (PRGO.N) said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker’s shares down about 8 percent.
TEVJF TEVA PRGO TEVVF
Perrigo Company plc (PRGO - Free Report) reported second-quarter 2018 adjusted earnings of $1.22 per share, which beat the Zacks Consensus Estimate of $1.21. Earnings growth was flat year over year.
SGEN VRTX PRGO UCTI OTCB UCTT
Perrigo (PRGO - Free Report) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items.
HCCDZ PRGO HCHC GWRS UCTI SND RLH UCTT
The second-quarter reporting cycle is coming to an end. Though the quarterly results were marked by all around positive surprises and plenty of momentum on the revenue side, the downtrend in earnings estimate revisions for the current period (third quarter 2018) is a concern.
OAS LOXO PRGO PBYI
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to PRGO / Perrigo Company plc on message board site Silicon Investor.
|PRGO: Perrigo Company||PRGO: Perrigo Company||PRGO: Perrigo Company|
as of ET